9 results
425
EX-2.1
IMNM
Immunome, Inc.
29 Jun 23
Business combination disclosure
9:10am
by shares, limited liability company or joint stock company), firm, society or other enterprise, association, organization or entity, and each of its
8-K
EX-2.1
IMNM
Immunome, Inc.
29 Jun 23
Immunome and Morphimmune Announce Definitive Merger Agreement
9:08am
by shares, limited liability company or joint stock company), firm, society or other enterprise, association, organization or entity, and each of its
8-K
EX-99.1
IMNM
Immunome, Inc.
14 Nov 22
Immunome Reports Third Quarter 2022 Financial Results
9:06am
at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting. In November 2022, Immunome announced that it presented a poster presentation … at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting. Immunome’s preclinical research of IMM20059 demonstrated that IMM20059
424B4
hulv8m
5 Oct 20
Prospectus supplement with pricing info
5:10pm
S-1/A
hrs8vt8
24 Sep 20
IPO registration (amended)
7:18am
S-1
8zf e2ss2d04u65k
9 Sep 20
IPO registration
4:19pm
DRS
2tbhxd
12 Aug 20
Draft registration statement
12:00am
- Prev
- 1
- Next